Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Doctors worried GLP-1 weight loss drugs might weaken bones, but new data says the opposite. Two large cohort studies found GLP-1 receptor agonists were linked to significantly lower fragility fracture risk in patients with obesity or type 2 diabetes, with the biggest reductions seen at the hip, spine, and forearm. Separately, semaglutide specifically showed a 15% lower fracture risk versus other weight-loss medications.
A common concern among physicians has been that GLP-1 receptor agonists — the blockbuster class behind Ozempic and Wegovy — might accelerate bone loss through rapid weight reduction. But mounting evidence is flipping that narrative. Two large cohort studies presented at the American Orthopaedic Foot & Ankle Society Annual Meeting found that GLP-1s were associated with lower fragility fracture risk in patients with obesity or type 2 diabetes, not higher.
In one study of over 348,000 patients with type 2 diabetes, GLP-1 users had lower fracture rates at trabecular-rich sites like the hip, spine, and arm — but notably, not the ankle, suggesting the effect is site-specific. A second study of nearly 284,000 patients with obesity (without diabetes) found a 30% lower fragility fracture risk overall among GLP-1 users. Separately, a Stanford-led retrospective study of ~59,000 adults with type 2 diabetes found semaglutide specifically linked to a 15% lower fracture risk versus other weight-loss drugs, alongside greater BMI reduction.
By the Numbers
Why it matters: These findings offer reassurance to the millions of patients and clinicians navigating GLP-1 therapy. While experts caution the data don't yet justify prescribing GLP-1s specifically to prevent fractures, they do suggest bone health shouldn't be a barrier to prescribing — and that musculoskeletal monitoring should be part of the conversation.
